Total Payments
$182,387
2024 Payments
$54,376
Companies
21
Transactions
261
Medicare Patients
10,885
Medicare Billing
$588,261
Payment Breakdown by Category
Other$122,971 (67.4%)
Consulting$30,943 (17.0%)
Travel$21,317 (11.7%)
Food & Beverage$6,279 (3.4%)
Research$823.75 (0.5%)
Education$53.52 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $122,971 | 49 | 67.4% |
| Consulting Fee | $30,943 | 12 | 17.0% |
| Travel and Lodging | $21,317 | 69 | 11.7% |
| Food and Beverage | $6,279 | 125 | 3.4% |
| Unspecified | $823.75 | 1 | 0.5% |
| Education | $53.52 | 5 | 0.0% |
Payments by Type
General
$181,563
260 transactions
Research
$823.75
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $137,975 | 144 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $11,591 | 19 | $0 (2018) |
| Gilead Sciences, Inc. | $11,152 | 18 | $0 (2018) |
| PFIZER INC. | $7,746 | 16 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $5,533 | 17 | $0 (2024) |
| Boston Scientific Corporation | $3,008 | 8 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $2,308 | 2 | $0 (2017) |
| Akcea Therapeutics, Inc. | $1,697 | 2 | $0 (2021) |
| Abbott Laboratories | $494.71 | 5 | $0 (2023) |
| Astellas Pharma US Inc | $258.01 | 15 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $54,376 | 54 | E.R. Squibb & Sons, L.L.C. ($54,181) |
| 2023 | $44,513 | 59 | E.R. Squibb & Sons, L.L.C. ($44,001) |
| 2022 | $40,513 | 50 | E.R. Squibb & Sons, L.L.C. ($37,967) |
| 2021 | $6,021 | 12 | PFIZER INC. ($2,300) |
| 2020 | $3,034 | 5 | PFIZER INC. ($3,006) |
| 2019 | $6,034 | 26 | Alnylam Pharmaceuticals Inc. ($5,514) |
| 2018 | $3,202 | 9 | Boston Scientific Corporation ($2,646) |
| 2017 | $24,692 | 46 | SANOFI-AVENTIS U.S. LLC ($11,575) |
All Payment Transactions
261 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,430.00 | General |
| Category: Cardiovascular | ||||||
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $78.57 | General |
| Category: Cardiovascular | ||||||
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Travel and Lodging | Cash or cash equivalent | $30.00 | General |
| Category: Cardiovascular | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,430.00 | General |
| Category: Cardiovascular | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $6.06 | General |
| Category: Cardiovascular | ||||||
| 11/17/2024 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 11/11/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Genetic Disease | ||||||
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,645.00 | General |
| Category: Cardiovascular | ||||||
| 10/15/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,166.00 | General |
| Category: Cardiovascular | ||||||
| 10/11/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,166.00 | General |
| Category: Cardiovascular | ||||||
| 10/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Travel and Lodging | Cash or cash equivalent | $1,655.09 | General |
| Category: Cardiovascular | ||||||
| 10/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Travel and Lodging | Cash or cash equivalent | $410.70 | General |
| Category: Cardiovascular | ||||||
| 09/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,712.50 | General |
| 09/21/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Travel and Lodging | Cash or cash equivalent | $786.24 | General |
| Category: Cardiovascular | ||||||
| 09/21/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Travel and Lodging | Cash or cash equivalent | $627.02 | General |
| Category: Cardiovascular | ||||||
| 09/21/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Travel and Lodging | Cash or cash equivalent | $486.21 | General |
| Category: Cardiovascular | ||||||
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Travel and Lodging | Cash or cash equivalent | $388.61 | General |
| Category: Cardiovascular | ||||||
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Travel and Lodging | Cash or cash equivalent | $208.13 | General |
| Category: Cardiovascular | ||||||
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Travel and Lodging | Cash or cash equivalent | $204.19 | General |
| Category: Cardiovascular | ||||||
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $101.11 | General |
| Category: Cardiovascular | ||||||
| 09/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $431.76 | General |
| 07/31/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,430.00 | General |
| Category: Cardiovascular | ||||||
| 07/31/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $6.39 | General |
| Category: Cardiovascular | ||||||
| 07/26/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $33.19 | General |
| Category: NEUROLOGY | ||||||
| 06/28/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM) | E.R. Squibb & Sons, L.L.C. | $823.75 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 2,824 | 3,103 | $387,381 | $140,474 |
| 2022 | 33 | 2,613 | 2,935 | $379,985 | $136,540 |
| 2021 | 31 | 2,704 | 3,031 | $417,621 | $158,265 |
| 2020 | 27 | 2,744 | 3,100 | $425,093 | $152,982 |
Total Patients
10,885
Total Services
12,169
Medicare Billing
$588,261
Procedure Codes
126
All Medicare Procedures & Services
126 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 338 | 403 | $81,406 | $31,943 | 39.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 534 | 562 | $70,250 | $26,942 | 38.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 75 | 150 | $29,850 | $13,169 | 44.1% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 108 | 110 | $22,550 | $8,281 | 36.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 60 | 63 | $24,444 | $8,005 | 32.7% |
| 93460 | Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 27 | 27 | $20,169 | $7,082 | 35.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 42 | $11,424 | $5,188 | 45.4% |
| 75563 | Mri scan of heart before and after contrast with stress imaging | Facility | 2023 | 44 | 44 | $13,640 | $3,920 | 28.7% |
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Facility | 2023 | 60 | 60 | $13,080 | $3,754 | 28.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 12 | 21 | $10,878 | $3,325 | 30.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 302 | 346 | $10,726 | $3,230 | 30.1% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 51 | 52 | $8,008 | $2,801 | 35.0% |
| 75561 | Mri scan of heart before and after contrast | Facility | 2023 | 25 | 25 | $6,750 | $2,305 | 34.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $5,057 | $2,101 | 41.5% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 139 | 140 | $6,020 | $2,082 | 34.6% |
| 93350 | Ultrasound of heart during rest, exercise and/or drug-induced stress with report | Facility | 2023 | 41 | 41 | $5,740 | $1,955 | 34.1% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 179 | 183 | $5,307 | $1,814 | 34.2% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 128 | 130 | $4,680 | $1,650 | 35.3% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 22 | 22 | $8,426 | $1,483 | 17.6% |
| 78803 | Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | Facility | 2023 | 38 | 39 | $3,978 | $1,475 | 37.1% |
| 78434 | Nuclear medicine study of heart muscle blood flow by pet | Facility | 2023 | 60 | 60 | $4,380 | $1,266 | 28.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 19 | 21 | $2,919 | $1,159 | 39.7% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 41 | 54 | $2,700 | $950.13 | 35.2% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 54 | 55 | $3,025 | $949.86 | 31.4% |
| 78800 | Nuclear medicine study, 1 area | Facility | 2023 | 38 | 39 | $2,535 | $888.42 | 35.0% |
About Dr. Mark Zenker, M.D
Dr. Mark Zenker, M.D is a Cardiovascular Disease healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316985120.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Zenker, M.D has received a total of $182,387 in payments from pharmaceutical and medical device companies, with $54,376 received in 2024. These payments were reported across 261 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($122,971).
As a Medicare-enrolled provider, Zenker has provided services to 10,885 Medicare beneficiaries, totaling 12,169 services with total Medicare billing of $588,261. Data is available for 4 years (2020–2023), covering 126 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Nashville, TN
- Active Since 06/03/2006
- Last Updated 07/10/2018
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1316985120
Products in Payments
- CAMZYOS (Drug) $89,934
- PRALUENT (Drug) $11,584
- Ranexa (Drug) $11,152
- VYNDAQEL (Drug) $7,667
- ONPATTRO (Drug) $5,514
- WATCHMAN (Device) $2,779
- PRALUENT ALIROCUMAB INJECTION (Biological) $2,308
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) $257.41
- Mitra Clip system (Device) $200.00
- WATCHMAN Access System (Device) $172.88
- LEXISCAN (Drug) $148.46
- Repatha (Biological) $139.91
- Impella (Device) $130.13
- Lexiscan (Drug) $109.55
- TEGSEDI (Drug) $104.10
- INSPIRE (Device) $75.42
- VERQUVO (Drug) $58.64
- CHANTIX (Drug) $53.15
- Rybelsus (Drug) $40.68
- ARCHITECT (Device) $37.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Nashville
Stephen Fahrig, Md, MD
Cardiovascular Disease — Payments: $679,196
Cardiovascular Disease $679,196
Dr. Gregory Bashian, M.d, M.D
Cardiovascular Disease — Payments: $485,755
Cardiovascular Disease $485,755
Dr. Hal Roseman, M.d, M.D
Cardiovascular Disease — Payments: $472,447
Cardiovascular Disease $472,447
Dr. Jimmy Kerrigan, Md, MD
Cardiovascular Disease — Payments: $414,382
Cardiovascular Disease $414,382
Dr. Colin Barker, M.d, M.D
Cardiovascular Disease — Payments: $393,788
Cardiovascular Disease $393,788
Joshua Beckman, Md, MD
Cardiovascular Disease — Payments: $201,658
Cardiovascular Disease $201,658